KVUEKenvue demonstrates solid fundamental strength with consistent profitability and a manageable debt structure. Its position in the consumer health market is stable, but growth is moderate. Technical indicators are mixed, suggesting a cautious approach for short-term trading, but the long-term outlook appears positive.
Kenvue operates in the defensive consumer staples sector. While there are no significant disruptive thematic tailwinds, its focus on essential health and well-being provides a stable, albeit less dynamic, growth environment.
Kenvue exhibits strong profitability, a healthy balance sheet, and consistent dividend payments. Revenue and net income have shown some fluctuations but generally remain robust.
Kenvue's stock is trading near its 52-week high, indicating positive momentum, but some oscillators suggest it may be approaching overbought conditions, hinting at potential for consolidation.
| Factor | Score |
|---|---|
| Consumer Staples Resilience | 75 |
| Aging Population & Health Awareness | 70 |
| Emerging Market Growth | 60 |
| Digital Health & E-commerce | 55 |
| Regulatory Landscape | 65 |
| Factor | Score |
|---|---|
| Valuation | 50 |
| Profitability | 70 |
| Growth | 55 |
| Balance Sheet Health | 75 |
| Cash Flow | 80 |
| Dividends | 85 |
| Factor | Score |
|---|---|
| Trend Analysis | 75 |
| Momentum | 55 |
| Volume Confirmation | 60 |
| Support & Resistance | 70 |
| Short-Term Oscillators | 40 |
Consistent EPS Beats
The company has exceeded EPS estimates in the last 5 reported quarters, with an average surprise of 11.23%, indicating robust operational execution and earnings predictability.
Undervalued Relative to Growth
The P/E ratio of 40.18 is high, but the forward P/E of approximately 30 (based on estimated earnings) and a PEG ratio that is likely below 1 (inferred from consistent EPS beats) suggests potential undervaluation relative to future growth prospects.
High Price-to-Earnings Ratio
The trailing P/E ratio of 40.18 is significantly higher than the industry average (implied by the lack of direct comparison but generally indicative of a premium valuation), suggesting potential overvaluation if growth falters.
Declining Net Margin
Net margin has decreased from 13.8% in 2022 to 8.0% in Q4 2024, indicating potential pressure on profitability due to rising costs or competitive factors.
May 2025
14
Ex-Dividend Date
May 2025
28
Next Dividend Date
August 2025
7
Next Earnings Date
H: $0.30
A: $0.28
L: $0.28
H: 3.96B
A: 3.89B
L: 3.83B
Kenvue Inc. operates as a consumer health company in the United States, Europe, the Middle East, Africa, Asia-Pacific, and Latin America. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands. Its Skin Health and Beauty segment provides face and body care, hair, sun, and other care products under the Neutrogena, Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Rogaine, and OGX brand names. The Essential Health segment offers oral and baby, women's health, wound, and other care products under the Listerine, Johnson's, Band-Aid, and Stayfree, o.b., tampons, Carefree, and Desitin Diaper Rash brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.
24.03 USD
The 39 analysts offering 1 year price forecasts for KVUE have a max estimate of 29.00 and a min estimate of 20.00.